AVITA MEDICAL INC (RCEL) Stock Price & Overview

NASDAQ:RCEL • US05380C1027

4.9 USD
-0.06 (-1.21%)
At close: Mar 10, 2026
4.9874 USD
+0.09 (+1.78%)
After Hours: 3/10/2026, 8:00:01 PM

The current stock price of RCEL is 4.9 USD. Today RCEL is down by -1.21%. In the past month the price increased by 20.99%. In the past year, price decreased by -42.69%.

RCEL Key Statistics

52-Week Range3.22 - 10.29
Current RCEL stock price positioned within its 52-week range.
1-Month Range3.52 - 5.92
Current RCEL stock price positioned within its 1-month range.
Market Cap
150.087M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.75
Dividend Yield
N/A

RCEL Stock Performance

Today
-1.21%
1 Week
+1.87%
1 Month
+20.99%
3 Months
+41.62%
Longer-term
6 Months +7.46%
1 Year -42.69%
2 Years -69.43%
3 Years -64.92%
5 Years -75.28%
10 Years N/A

RCEL Stock Chart

AVITA MEDICAL INC / RCEL Daily stock chart

RCEL Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to RCEL. When comparing the yearly performance of all stocks, RCEL is a bad performer in the overall market: 64.88% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
RCEL Full Technical Analysis Report

RCEL Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to RCEL. Both the profitability and financial health of RCEL have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RCEL Full Fundamental Analysis Report

RCEL Earnings

On January 13, 2026 RCEL reported an EPS of -0.38 and a revenue of 17.62M. The company missed EPS expectations (-10.88% surprise) and missed revenue expectations (-1.13% surprise).

Next Earnings DateMay 6, 2026
Last Earnings DateJan 13, 2026
PeriodQ4 / 2025
EPS Reported-$0.38
Revenue Reported17.616M
EPS Surprise -10.88%
Revenue Surprise -1.13%
RCEL Earnings History

RCEL Forecast & Estimates

12 analysts have analysed RCEL and the average price target is 6.32 USD. This implies a price increase of 29.06% is expected in the next year compared to the current price of 4.9.

For the next year, analysts expect an EPS growth of 55.02% and a revenue growth 19.9% for RCEL


Analysts
Analysts80
Price Target6.32 (28.98%)
EPS Next Y55.02%
Revenue Next Year19.9%
RCEL Forecast & Estimates

RCEL Groups

Sector & Classification

RCEL Financial Highlights

Over the last trailing twelve months RCEL reported a non-GAAP Earnings per Share(EPS) of -1.75. The EPS increased by 26.78% compared to the year before.


Income Statements
Revenue(TTM)71.61M
Net Income(TTM)-48.59M
Industry RankSector Rank
PM (TTM) N/A
ROA -86.16%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%13.64%
Sales Q2Q%-4.29%
EPS 1Y (TTM)26.78%
Revenue 1Y (TTM)11.45%
RCEL financials

RCEL Ownership

Ownership
Inst Owners15.86%
Shares30.63M
Float30.20M
Ins Owners1.37%
Short Float %12.4%
Short Ratio15.84
RCEL Ownership

RCEL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.3402.17B
AMGN AMGEN INC16.45203.213B
GILD GILEAD SCIENCES INC16.81182.029B
VRTX VERTEX PHARMACEUTICALS INC25.75117.075B
REGN REGENERON PHARMACEUTICALS16.5182.631B
ALNY ALNYLAM PHARMACEUTICALS INC43.2142.915B
INSM INSMED INC N/A30.852B
NTRA NATERA INC N/A29.086B
BIIB BIOGEN INC11.7227.626B
UTHR UNITED THERAPEUTICS CORP17.9423.193B
MRNA MODERNA INC N/A22.014B
EXAS EXACT SCIENCES CORP340.0819.797B
RVMD REVOLUTION MEDICINES INC N/A19.775B

About RCEL

Company Profile

RCEL logo image AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 226 full-time employees. The company went IPO on 2012-03-18. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.

Company Info

IPO: 2012-03-18

AVITA MEDICAL INC

28159 Avenue Stanford, Suite 220

Valencia California CALIFORNIA 91355 US

CEO: Michael Perry

Employees: 226

RCEL Company Website

RCEL Investor Relations

Phone: 16613679170

AVITA MEDICAL INC / RCEL FAQ

What does AVITA MEDICAL INC do?

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 226 full-time employees. The company went IPO on 2012-03-18. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.


What is the stock price of AVITA MEDICAL INC today?

The current stock price of RCEL is 4.9 USD. The price decreased by -1.21% in the last trading session.


What is the dividend status of AVITA MEDICAL INC?

RCEL does not pay a dividend.


What is the ChartMill rating of AVITA MEDICAL INC stock?

RCEL has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


How is the valuation of AVITA MEDICAL INC (RCEL) based on its PE ratio?

AVITA MEDICAL INC (RCEL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.75).


What is the market capitalization of RCEL stock?

AVITA MEDICAL INC (RCEL) has a market capitalization of 150.09M USD. This makes RCEL a Micro Cap stock.


Can you provide the short interest for RCEL stock?

The outstanding short interest for AVITA MEDICAL INC (RCEL) is 12.4% of its float.